In this randomized , open-label , international phase @ study , we assigned patients with nonsquamous non-small-cell lung cancer ( NSCLC ) that had progressed during or after platinum-based doublet chemotherapy to receive nivolumab at a dose of @ mg per kilogram of body weight every @ weeks or docetaxel at a dose of @ mg per square meter of body-surface area every @ weeks .